Table 2 Clinical characteristics and endpoints.
| All | Exercise | Pharmacological | |
|---|---|---|---|
| Number | 7452 | 5156 | 2296 |
| Age | 51 (SD 14) | 48 (SD 12) | 58 (SD 14)* |
| Women (%) | 4098 (55) | 2638 (51) | 1460 (64)* |
| Oestrogen status negative (%) | 1566 (38) | 732 (28) | 834 (57)* |
| Symptoms | |||
| Typical (%) | 498 (7) | 340 (7) | 158 (7) |
| Atypical (%) | 3041 (41) | 2063 (40) | 978 (43) |
| Non‐anginal (%) | 3913 (52) | 2753 (53) | 1160 (50) |
| Diabetes (%) | 1154 (16) | 536 (10) | 618 (27)* |
| Smoking (%) | 3600 (48) | 2391 (46) | 1209 (53)* |
| Hyperlipidaemia (%) | 2401 (32) | 1556 (30) | 845 (37)* |
| Hypertension (%) | 3075 (41) | 1734 (34) | 1341 (58)* |
| Obesity (%) | 4801 (64) | 3205 (62) | 1596 (70)* |
| Family history (%) | 3591 (48) | 2537 (49) | 1054 (46)† |
| Pretest score | 10 (SD 5) | 9 (SD 4) | 12 (SD 4)* |
| New pretest score group | |||
| Low (%) | 2881 (39) | 2400 (47) | 481 (21) |
| Intermediate (%) | 3584 (48) | 2350 (46) | 1234 (54)* |
| High (%) | 987 (13) | 406 (7) | 581 (25) |
| All‐cause death | 431 (5.8, 1.3) | 154 (3.0, 0.7) | 277 (12, 2.8)* |
| Cardiac death | 151 (2.0, 0.5) | 43 (0.8, 0.2) | 108 (4.7, 1.1)* |
| Non‐fatal MI | 121 (1.6, 0.4) | 71 (1.4, 0.3) | 50 (2.2, 0.5)† |
| CD/MI | 264 (3.5, 0.8) | 109 (2.1, 0.5) | 155 (6.8, 1.6)* |
| Revascularisation | 440 (5.9, 1.4) | 258 (5.0, 1.2) | 182 (7.9, 1.8)* |
CD, cardiac death, MI, myocardial infarction; SD, standard deviation.
(n, n), (raw %, annualised %).
*p<0.001, †p<0.05 v Exercise group.